# US 6,727,270 B2 · Pyrrolylalkylidene-hydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,270 B2
- Document ID: US6727270B2
- Status: Granted
- Kind: B2
- Application number: 10/366,011
- Filed: 2003-02-13
- Published: 2003-10-30
- Granted: 2004-04-27
- Earliest claimed: 2002-02-14
- Assignees: Wyeth
- Inventors: Michael Gerard Kelly; Ping Zhou
- Web page: https://patentgrep.com/patent/US6727270B2

## CPC

- C07D 409/12: linked by a chain containing hetero atoms as chain links
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- C07D 207/48: Sulfur atoms
- C07D 209/08: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.

## Claims

### Claim 1

A compound of formula I
wherein
Q is SO2, CO, CH2, CO2, CONH or CSNH;
R1, R2, R3 and R4 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C10cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted or R1 and R2 may be taken together with the atoms to which they are attached to form a 5-, 6- or 7-membered ring;
R5 is H or R4 and R5 may be taken together with the atoms to which they are attached to form a 5-, 6- or 7-membered ring;
R6 is a C1-C6alkyl, aryl or heteroaryl group each optionally substituted;
R7 is H, halogen, NO2, CN, OR8, NR9R10, OCO2R11, OCONR12R13, CO2R14, COR15, CONR16R17 or SO2NR18R19 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R8, R11, R14 and R15 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; and
R9, R10, R12, R13, R16, R17, R18 and R19 are each independently H or an optionally substituted C1-C6alkyl group or R9 and R10 may be taken together with the atom to which they are attached to form a 5-, 6- or 7-membered ring optionally containing another heteroatom selected from O, N or S; or
the stereoisomers thereof or the pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

The compound according to claim 1 wherein Q is SO2.

### Claim 3 (depends on 1)

The compound according to claim 1 wherein R5 is H.

### Claim 4 (depends on 2)

The compound according to claim 2 wherein R6 is an optionally substituted aryl or heteroaryl group.

### Claim 5

The compound according to 4 wherein R4 is H or CH3 and R5 is H.

### Claim 6 (depends on 5)

The compound according to claim 5 wherein R6 is an optionally substituted phenyl or heteroaryl group.

### Claim 7 (depends on 6)

The compound according to claim 6 wherein R7 is H.

### Claim 8 (depends on 7)

The compound according to claim 7 wherein R1, R2 and R3 are H.

### Claim 9 (depends on 2)

The compound according to claim 2 selected from the group consisting of:
2-{(E)-1-[1-(phenylsulfonyl)-1H-pyrrol-3-yl]ethylidene}hydrazinecarboximidamide;
2-{(E)-1-[1-(4-methylphenylsulfonyl)-1H-pyrrol-3-yl]ethylidene}hydrazine-carboximidamide;
2-{(E)-1-[1-(2,4-dimethyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]ethylidene}hydrazine-carboximidamide;
2-{(E)-1-[1-(naphthylsulfonyl)-1H-pyrrol-3-yl]ethylidene}-1-hydrazine-carboximidamide;
2-{(E)-1-{1-(5-chloro-3-methyl-1-benzothiophen-2-yl)sulfonyl]-1H-pyrrol-3-yl}ethylidene)-1-hydrazinecarboximidamide;
2-((E)-1-{1-[(4-aminophenyl)sulfonyl]-1H-pyrrol-3-yl}ethylidene)-1-hydrazine-carboximidamide;
2-((E)-1-{1-[(2-amino-4-methyl-1,3-thiazol-5-yl)sulfonyl]-1H-pyrrol-3-yl)}ethylidene)-1-hydrazinecarboximidamide;
2-[1-[(phenylsulfonyl)-1,5,6,7-tetrahydro-4H-indol-4-ylidene]-1-hydrazinecarboximidamide;
2-[1-(4-biphenylsulfonyl)-1,5,6,7-tetrahydro-4H-indol-4-ylidene]-1-hydrazinecarboximidamide;
2-[1-(4-bromophenylsulfonyl)-1,5,6,7-tetrahydro-4H-indol-4-ylidene]-1-hydrazinecarboximidamide;
2-[1-(5-chloro-2-methoxyphenylsulfonyl)-1,5,6,7-tetrahydro-4H-indol-4-ylidene]-1-hydrazinecarboximidamide;
the stereoisomers thereof; and
the pharmaceutically acceptable salts thereof.

### Claim 10

A method for the treatment of a disorder of the central nervous system related to or affected by the 5-HT6 receptor wherein said disorder is selected from the group consisting of motor disorder, anxiety disorder, cognitive disorder, schizophrenia, depression, Alzheimer's disease, Parkinson's disease, attention deficit disorder and obsessive compulsive disorder, in a patient in need thereof which comprises providing to said patient a therapeutically effective amount of a compound of formula I
wherein
Q is SO2, CO, CH2, CO2, CONH or CSNH;
R1, R2, R3 and R4 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C10cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted or R1 and R2 may be taken together with the atoms to which they are attached to form a 5-, 6- or 7-membered ring;
R5 is H or R4 and R5 may be taken together with the atoms to which they are attached to form a 5-, 6- or 7-membered ring;
R6 is a C1-C6alkyl, aryl or heteroaryl group each optionally substituted;
R7 is H, halogen, NO2, CN, OR8, NR9R10, OCO2R11, OCONR12R13, CO2R14, COR15, CONR16R17 or SO2NR18R19 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R8, R11, R14 and R15 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; and
R9, R10, R12, R13, R16, R17, R18 and R19 are each independently H or an optionally substituted C1-C6alkyl group or R9 and R10 may be taken together with the atom to which they are attached to form a 5-, 6- or 7-membered ring optionally containing another heteroatom selected from O, N or S; or
the stereoisomers thereof or the pharmaceutically acceptable salts thereof.

### Claim 11 (depends on 10)

The method according to claim 10 wherein said disorder is a motor disorder, anxiety disorder or cognitive disorder.

### Claim 12 (depends on 10)

The method according to claim 10 wherein said disorder is schizophrenia or depression.

### Claim 13 (depends on 11)

The method according to claim 11 wherein said disorder is selected from the group consisting of: Alzheimer's disease; Parkinson's disease; attention deficit disorder; and obsessive compulsive disorder.

### Claim 14 (depends on 11)

The method according to claim 11 having a formula I compound wherein Q is SO2; R4 is H or CH3; R5 is H; and R6 is an optionally substituted phenyl or heteroaryl group.

### Claim 15

A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I
wherein
Q is SO2, CO, CH2, CO2, CONH or CSNH;
R1, R2, R3 and R4 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C10cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted or R1 and R2 may be taken together with the atoms to which they are attached to form a 5-, 6- or 7-membered ring;
R5 is H or R4 and R5 may be taken together with the atoms to which they are attached to form a 5-, 6- or 7-membered ring;
R6 is a C1-C6alkyl, aryl or heteroaryl group each optionally substituted;
R7 is H, halogen, NO2, CN, OR8, NR9R10, OCO2R11, OCONR12R13, CO2R14, COR15, CONR16R17 or SO2NR18R19 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R8, R11, R14 and R15 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; and
R9, R10, R12, R13, R16, R17, R18 and R19 are each independently H or an optionally substituted C1-C6alkyl group or R9 and R10 may be taken together with the atom to which they are attached to form a 5-, 6- or 7-membered ring optionally containing another heteroatom selected from O, N or S; or
the stereoisomers thereof or the pharmaceutically acceptable salts thereof.

### Claim 16 (depends on 15)

The composition according to claim 15 having a formula I compound wherein Q is SO2.

### Claim 17 (depends on 16)

The composition according to claim 16 having a formula I wherein R4 is H or CH3 and R5 and R7 are H.

### Claim 18 (depends on 17)

The composition according to claim 17 having a formula I compound wherein R6 is an optionally substituted phenyl or heteroaryl group.

### Claim 19 (depends on 16)

The composition according to claim 16 having a formula I compound selected from the group consisting of:
2-{(E)-1-[1-(phenylsulfonyl)-1H-pyrrol-3-yl]ethylidene}hydrazinecarboximidamide;
2-{(E)-1-[1-(4-methylphenylsulfonyl)-1H-pyrrol-3-yl]ethylidene}hydrazine-carboximidamide;
2-{(E)-1-[1-(2,4-dimethyl-1-(phenylsulfonyl)-1H-pyrrol-3-yl]ethylidene}hydrazine-carboximidamide;
2-{(E)-1-[1-(naphthylsulfonyl)-1H-pyrrol-3-yl]ethylidene}-1-hydrazine-carboximidamide;
2-{(E)-1-{1-(5-chloro-3-methyl-1-benzothiophen-2-yl)sulfonyl]-1H-pyrrol-3-yl}ethylidene)-1-hydrazinecarboximidamide;
2-((E)-1-{1-[(4-aminophenyl)sulfonyl]-1H-pyrrol-3-yl}ethylidene)-1-hydrazine-carboximidamide;
2-((E)-1-{1-[(2-amino-4-methyl-1,3-thiazol-5-yl)sulfonyl]-1H-pyrrol-3-yl}ethylidene)-1-hydrazinecarboximidamide;
2-[1-[(phenylsulfonyl)-1,5,6,7-tetrahydro-4H-indol-4-ylidene]-1-hydrazinecarboximidamide;
2-[1-(4-biphenylsulfonyl)-1,5,6,7-tetrahydro-4H-indol-4-ylidene]-1-hydrazinecarboximidamide;
2-[1-(4-bromophenylsulfonyl)-1,5,6,7-tetrahydro-4H-indol-4-ylidene]-1-hydrazinecarboximidamide;
2-[1-(5-chloro-2-methoxyphenylsulfonyl)-1,5,6,7-tetrahydro-4H-indol-4-ylidene]-1-hydrazinecarboximidamide;
the stereoisomers thereof; and
the pharmaceutically acceptable salts thereof.

### Claim 20

A process for the preparation of a compound of formula I
wherein
Q is SO2, CO, CH2, CO2, CONH or CSNH;
R1, R2, R3 and R4 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C10cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted or R1 and R2 may be taken together with the atoms to which they are attached to form a-5-, 6- or 7-membered ring;
R5 is H or R4 and R5 may be taken together with the atoms to which they are attached to form a 5-, 6- or 7-membered ring;
R6 is a C1-C6alkyl, aryl or heteroaryl group each optionally substituted;
R7 is H, halogen, NO2, CN, OR8, NR9R10, OCO2R11, OCONR12R13, CO2R14, COR15, CONR16R17 or SO2NR18R19 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R8, R11, R14 and R15 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; and
R9, R10, R12, R13, R16, R17, R18 and R19 are each independently H or an optionally substituted C1-C6alkyl group or R9 and R10 may be taken together with the atom to which they are attached to form a 5-, 6- or 7-membered ring optionally containing another heteroatom selected from O, N or S
which process comprises reacting a compound of formula
wherein Q, R4, R5, R6 and R7 are as described hereinabove with an aminoguanidine of formula IV
wherein R1, R2 and R3 are described hereinabove in the presence of an acid optionally in the presence of a solvent.
